Searching for new cancer biomarkers, circulating cell-free DNA (cfDNA) has become an appealing target of interest as an elevated level of cfDNA has been detected in the circulation of cancer patients in comparison with healthy controls. Since cfDNA can be isolated from the circulation and other body fluids of patients without harming their physical condition, cfDNA is becoming a promising candidate as a novel non-invasive biomarker for cancer. The challenge in the diagnostic analysis of cfDNA is its very low presence in human plasma/serum and its partially strong fragmentation. Here we evaluated a modified phenol/chloroform extraction method for the isolation of cfDNA and compared it with published standard methods for cfDNA isolation.
Protocol
Searching for new cancer biomarkers, circulating cell-free DNA (cfDNA) has become an appealing target of interest as an elevated level of cfDNA has been detected in the circulation of cancer patients in comparison with healthy controls. Since cfDNA can be isolated from the circulation and other body fluids of patients without harming their physical condition, cfDNA is becoming a promising candidate as a novel non-invasive biomarker for cancer. [1] [2] [3] The challenge in the diagnostic analysis of cfDNA is its very low presence in human plasma and its partially strong fragmentation. 2 Here we evaluated a modified phenol/chloroform extraction method for the isolation of cfDNA in human plasma and compared it with published standard methods for cfDNA isolation. 4 Although cfDNA was about 5-fold higher in serum samples compared to plasma (data not shown. 5 We only show cfDNA levels determined from plasma samples which allows a better comparison with previously published protocols. [6] [7] [8] Therefore, plasma samples from healthy individuals (n=10) and patients with colon carcinoma (n=15) and breast cancer (n=15) were analyzed in parallel using our modified phenol/chloroform method in comparison to the Maxwell ® 16 LEV ® Plasma XS (Macherey-Nagel) 8 and a published Phenol-chloroform extraction method. 6 The samples were processed to obtain plasma within an hour after the withdrawal of blood from donors. The plasma was obtained by two centrifugations of whole blood EDTA-tubes at 1500 g at 4 C° for 10 min and at 3000g at 4°C for 10min, and was then preserved at -80°C. To 1 mL of plasma, 100 µL of a solution containing 250 mmol/L EDTA and 750 mmol/L NaCl, 100 µL of 100 g/L sodium dodecyl sulfate and 20 µL of proteinase K (final concentration 20 mg/mL) was added. The samples were incubated for 2 hours at 56°C, and the proteins were precipitated with 200 µL of saturated 6M NaCl solu-
min at room temperature the solution was centrifuged for 15 min at 14,000 g. The cleared supernatant was transferred into a new tube and the DNA was precipitated by adding the same volume of absolute ethanol and incubating overnight at -20°C. The DNA was first centrifuged for 15 min at 14,000 g, then washed with 70% ethanol and dissolved in 50 µL water. We used 5 µL of template DNA for quantification, and each sample was analyzed in duplicate. The DNA was quantified by a real-time PCR analysis using the sequence of hTERT, the human telomerase reverse transcriptase. 7 The amplicon size of the hTERT single copy gene was 98 bp. As shown in Table 1 , our modified cfDNA extraction method was superior to all tested kit-based standard extraction methods and led also to a DNA yield which was about four times higher compared to the recently published method by Schmidt et al., 6 which is similar to our presented protocol. However, Schmidt et al describe the isolation of cfDNA within 2 working days, whereupon we decided to set up a protocol aiming at completing cfDNA purification within only one working day. To achieve this, we performed a single DNA precipitation, whereas Schmidt et al performed two consecutive rounds of precipitations. As DNA gets lost with every round of precipitation, omitting the second precipitation step may at least in part explain the higher amount of cfDNA gained by our protocol. In addition, the slightly different salt concentration used for cfDNA precipitation may also account for the higher efficiency of our method.
Regarding the fragment-length of the isolated cell free DNA we were able to detect fragments from 100 pb up to 600 bp via PCR, 9 isolated with all methods but noticed a higher fragmentation of cfDNA in patients compared to healthy controls ( Figure 1 and Table 2 ). 10 However, the presence of sequences shorter than 98 bp as early marker for the attendance of tumors was not examinated in this study (Moulière et al. personal communication) .
Regarding the clinical aspects we were able to detect tumor-specific mutations (KRAS codon 12-13 and BRAF V600E point mutations)
11-14 and we found significantly increased levels of cell-free DNA in patients compared to controls, which is in line with former published data (Figures 2 and 3) . 3, [15] [16] [17] [18] [19] [20] In summary, we were able to show a simple and robust method for extraction, isolation and analysis of cfDNA, suitable for a routine clinical-oncology laboratory. In addition, this method was suitable for further PCR-based characterization sequencing applications. Table 2 

